News
-
3 min
iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing
-
3 min
iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital
-
1 min
iQ-007 Accepted into Prestigious NIH Preclinical Screening Platform for Pain (PSPP) Program
-
2 min
iQure Pharma’s iQ-007 Completes Critical Go/No Go Criteria - September Start for MTD & GLP Tox Study
-
2 min
iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Pain & Epilepsy
-
2 min
iQure Pharma’s iQ-007 Passes Cardiac Safety Test–Critical Milestone for GLP Toxicology Studies
-
1 min
iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone
-
1 min
iQure Pharma’s iQ-007 & iQ-008 Compounds Continue to Deliver Promising Results
-
1 min
iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023
-
1 min
iQ-007 shows no abuse potential in FDA recommended panel of tests
-
1 min
iQure Pharma researchers seek non-opioid alternatives to manage pain
